Melanie E Bennett1,2, Kristen R Bradshaw3, Lauren T Catalano3. 1. a Department of Psychiatry , University of Maryland School of Medicine , Baltimore , MD , USA. 2. b VA VISN 5 Mental Illness Research, Education, and Clinical Center , Baltimore , MD , USA. 3. c Department of Psychology , University of Maryland, College Park , College Park , MD , USA.
Abstract
BACKGROUND: Substance use disorders (SUDs) represent a great barrier to functional recovery for individuals with schizophrenia. It is important to use research on treatment of SUDs in schizophrenia to guide treatment recommendations and program planning. OBJECTIVES: We review studies of pharmacological and psychosocial interventions to treat SUDs in individuals with schizophrenia. METHODS: The criteria used to select studies for inclusion are (1) the percentage of the sample with a schizophrenia spectrum diagnosis is at least 25%; (2) participants have a comorbid SUD or problem use of substances; (3) an intervention for SUD is provided; (4) a substance use-related outcome is measured; and (5) the study design enabled examination of pre-post outcome measures including open label trials, nonrandomized evaluations (quasi-experimental designs, nonrandom assignment to groups), or randomized controlled trials. RESULTS: There are few psychopharmacology outcomes studies. Most have examined use of antipsychotic medications to treat SUDs in schizophrenia. Several trials have yielded positive findings for naltrexone in reducing drinking compared to placebo in this population. Motivational and cognitive-behavioral interventions are associated with decreased substance use in several trials. CONCLUSION: Treatment for SUDs is feasible within a range of settings and acceptable to many individuals with schizophrenia. All individuals with schizophrenia should be offered brief or more extended psychosocial interventions that incorporate discussion of personal reasons to change and training in cognitive-behavioral strategies to reduce use, cope with cravings and stress, and avoid relapse. Future research must include larger samples, longitudinal designs, and similar outcome measures across studies.
BACKGROUND: Substance use disorders (SUDs) represent a great barrier to functional recovery for individuals with schizophrenia. It is important to use research on treatment of SUDs in schizophrenia to guide treatment recommendations and program planning. OBJECTIVES: We review studies of pharmacological and psychosocial interventions to treat SUDs in individuals with schizophrenia. METHODS: The criteria used to select studies for inclusion are (1) the percentage of the sample with a schizophrenia spectrum diagnosis is at least 25%; (2) participants have a comorbid SUD or problem use of substances; (3) an intervention for SUD is provided; (4) a substance use-related outcome is measured; and (5) the study design enabled examination of pre-post outcome measures including open label trials, nonrandomized evaluations (quasi-experimental designs, nonrandom assignment to groups), or randomized controlled trials. RESULTS: There are few psychopharmacology outcomes studies. Most have examined use of antipsychotic medications to treat SUDs in schizophrenia. Several trials have yielded positive findings for naltrexone in reducing drinking compared to placebo in this population. Motivational and cognitive-behavioral interventions are associated with decreased substance use in several trials. CONCLUSION: Treatment for SUDs is feasible within a range of settings and acceptable to many individuals with schizophrenia. All individuals with schizophrenia should be offered brief or more extended psychosocial interventions that incorporate discussion of personal reasons to change and training in cognitive-behavioral strategies to reduce use, cope with cravings and stress, and avoid relapse. Future research must include larger samples, longitudinal designs, and similar outcome measures across studies.
Entities:
Keywords:
Schizophrenia; serious mental illness; substance use disorders; treatment
Authors: Alexandria S Coles; Dunja Knezevic; Tony P George; Christoph U Correll; John M Kane; David Castle Journal: Front Psychiatry Date: 2021-12-15 Impact factor: 4.157
Authors: Samantha Johnstone; Maryam Sorkhou; Nada Al-Saghir; Darby J E Lowe; Vaughn R Steele; Godfrey D Pearlson; David J Castle; Tony P George Journal: Front Psychiatry Date: 2022-02-14 Impact factor: 4.157